NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Brief Update of Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Free Report ) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 385,600 shares, a decrease of 18.1% from the August 31st total of 470,700 shares. Currently, 2.7% of the company’s shares are short sold. Based on an average trading volume of 392,400 shares, the short interest rate is currently 1.0 days.

NeuroSense Therapeutics price performance

Shares of NRSN traded up $0.01 during midday trading on Friday, hitting $1.28. The stock had a trading volume of 64,438 shares compared to its average volume of 278,903. NeuroSense Therapeutics has a 1 year low of $0.40 and a 1 year high of $2.33. The stock’s 50-day moving average is $0.93 and its 200-day moving average is $1.16. The firm has a market cap of $17.49 million, a PE ratio of -1.51 and a beta of 1.52.

Institutional Trade of NeuroSense Therapy

A hedge fund recently bought a new stake in shares of NeuroSense Therapeutics. Armistice Capital LLC bought a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,584,000 shares of the company’s stock, valued at approximately $1,774,000. Armistice Capital LLC owned about 11.59% of NeuroSense Therapeutics as of its most recent filing with the Securities & Exchange Commission. 1.04% of the shares are held by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

(Get a free report)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently in phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis and has completed phase 2 clinical trials for the treatment of Alzheimer’s, as well as in preclinical studies for the treatment of Parkinson’s disease.

Further reading

Get daily news and reviews for NeuroSense Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeuroSense Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.